Medipharm Labs Corp T.LABS

Who will know first? Well look at the government as a

[subaru1i]

company with departments.  The DEA will notifiy the White House, FDA and NIH well BEFORE they contact the press for the annoucment.   The FDA will notifiy the submitter of the NDA and 505(b) before they contact the press as well.   I am saying the global pharma partner is Pfizer so Bourla will get the call from the FDA before it hits the news wires.  Why important to share this?

We might see a major announcement made regarding LABS and their traditioinal global pharmaceutical partner BEFORE any news is made public from the DEA.

Athea and I discussed this last night in the kitchen but it was too late to make the post and we had 'other plans'.   

Do NOT be caught off guard thinking we are waiting for the DEA news of rescheduling to become public.

[okgonow]

hate to let the air out of the balloon a little but Rescheduling could languish in court if money doesn't brick behind its support. The U.S. Department of Health and Human Services’ proposal to reclassify cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act faces an uncertain effective date due and potential legal battles. The

[okgonow]

Also This   For many, the most exciting prospect in the cannabis industry for 2024 is the possibility of rescheduling cannabis from a Schedule I controlled substance to Schedule III under the Controlled Substances Act (as amended and in effect, the “CSA”). Rescheduling would be a marked step forward for the legal cannabis industry and provide much-needed financial relief to

[subaru1i]

This is NOT at all about rescheduling for recreational.  The request came from the White House, FDA, and NIH so it IS all about the pharmaceutical applications.     Matter a fact, once rescheduled by the DEA, they could reschedule it with a conditional clause and that conditional clause would be for PHARMACEUTICAL APPLICATIONS.